Oruka Therapeutics (NASDAQ:ORKA – Get Free Report) and Coya Therapeutics (NASDAQ:COYA – Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, earnings, analyst recommendations, valuation and risk.
Profitability
This table compares Oruka Therapeutics and Coya Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Oruka Therapeutics | N/A | -21.65% | -20.88% |
| Coya Therapeutics | -270.22% | -52.05% | -46.34% |
Earnings and Valuation
This table compares Oruka Therapeutics and Coya Therapeutics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Oruka Therapeutics | N/A | N/A | -$105.43 million | ($2.03) | -54.70 |
| Coya Therapeutics | $8.02 million | 14.01 | -$21.23 million | ($1.07) | -4.48 |
Coya Therapeutics has higher revenue and earnings than Oruka Therapeutics. Oruka Therapeutics is trading at a lower price-to-earnings ratio than Coya Therapeutics, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Oruka Therapeutics has a beta of -0.34, indicating that its stock price is 134% less volatile than the S&P 500. Comparatively, Coya Therapeutics has a beta of 0.6, indicating that its stock price is 40% less volatile than the S&P 500.
Analyst Recommendations
This is a summary of recent recommendations for Oruka Therapeutics and Coya Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Oruka Therapeutics | 1 | 0 | 10 | 0 | 2.82 |
| Coya Therapeutics | 1 | 0 | 6 | 0 | 2.71 |
Oruka Therapeutics presently has a consensus target price of $134.30, indicating a potential upside of 20.95%. Coya Therapeutics has a consensus target price of $15.33, indicating a potential upside of 220.11%. Given Coya Therapeutics’ higher possible upside, analysts clearly believe Coya Therapeutics is more favorable than Oruka Therapeutics.
Institutional and Insider Ownership
56.4% of Oruka Therapeutics shares are held by institutional investors. Comparatively, 39.8% of Coya Therapeutics shares are held by institutional investors. 23.5% of Oruka Therapeutics shares are held by insiders. Comparatively, 6.1% of Coya Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Summary
Oruka Therapeutics beats Coya Therapeutics on 7 of the 13 factors compared between the two stocks.
About Oruka Therapeutics
Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.
About Coya Therapeutics
Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic, which is in Phase 2 clinical trial for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas.
Receive News & Ratings for Oruka Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oruka Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
